Related Experiment Video
Updated: Jun 3, 2026
13:36
Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
Lessons drawn from recent HIV vaccine efficacy trials
Jonathan D Fuchs1, Magda E Sobieszczyk, Scott M Hammer
1HIV Research Section, San Francisco Department of Public Health, San Francisco, CA 94102, USA. jonathan.fuchs@sfdph.org
Journal of Acquired Immune Deficiency Syndromes (1999)
|March 17, 2011
Summary
Despite decades of research, an effective HIV vaccine remains elusive. Recent trials, like RV144, offer hope and valuable lessons for future HIV vaccine development and deployment.
Area of Science:
- Immunology
- Vaccinology
- Epidemiology
Background:
- The urgent need for a safe and effective human immunodeficiency virus (HIV) vaccine persists globally.
- Over 25 years of dedicated research have yet to yield a successful HIV vaccine.
- The RV144 Thai efficacy trial has provided renewed optimism for vaccine-induced protection against HIV acquisition.
Purpose of the Study:
- To analyze scientific and operational lessons learned from the RV144 trial and other HIV vaccine concept efficacy studies.
- To highlight the critical role of clinical studies in advancing HIV vaccine discovery.
- To emphasize the importance of transparency and community engagement in HIV vaccine research.
Main Methods:
- Review of results from the RV144 Thai efficacy trial.
- Analysis of data from other recent HIV vaccine tests-of-concept efficacy trials.
- Examination of scientific and operational outcomes, including unexpected findings.
Main Results:
- Unexpected trial results underscore the fundamental role of clinical studies in HIV vaccine discovery.
- Transparency in data analysis and dissemination significantly benefits research progress.
- Community engagement is crucial for enhancing research literacy and improving trial recruitment.
Conclusions:
- Lessons from recent efficacy trials provide a roadmap for future HIV vaccine development.
- Future trials may integrate partially effective prevention strategies alongside vaccines.
- Larger, more complex trials offer opportunities to explore vaccine and prevention strategy synergies.
Related Concept Videos
01:51Vaccinations
Overview
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:21Vaccines
Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
01:23Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...